Dipeptidyl Peptidase-4 Inhibitors Associated Heart Failure Events in Adult Patients With Type-2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis.
Shishir Nepal, Shiva Prasad Nepal
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and heart failure events in adult patients with type-2 diabetes. Analyzing data from 29 randomized controlled trials involving 67,873 patients, the study found a statistically insignificant overall risk ratio of 1.06 (95% CI 0.94-1.12) for heart failure events. However, saxagliptin was significantly associated with increased heart failure risk.
Key findings
- The overall risk ratio for heart failure events with DPP-4 inhibitors was 1.06 (95% CI 0.94-1.12).
- Saxagliptin use was significantly associated with an increased risk of heart failure.
- The analysis included 29 randomized controlled trials with a total of 67,873 patients.
Why it matters
Understanding the cardiovascular risks associated with diabetes medications is crucial for clinicians managing patients with type-2 diabetes, particularly in those with existing cardiovascular conditions. This study highlights the need for careful consideration of DPP-4 inhibitors, especially saxagliptin.